organization · Reporting owner
Devon Park Associates, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ROCKET PHARMACEUTICALS, INC.
Report date January 04, 2017 · Filed January 06, 2017
Jointly reported with DEVON PARK BIOVENTURES LP, Devon Park Associates, L.P.
Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 9,857 |
Reported balance
After 2017-01-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-01-04 · Other · Disposed 3,243,709 · Balance 9,857 F1: Devon Park Bioventures, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it. F2: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Bioventures, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2017-01-04 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-01-04 · Other · Disposed 9,857 · Balance 0 F3: Devon Park Associates, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it. F4: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Associates, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P. |
Filing footnotes · ownership attribution and instrument terms
F1: Devon Park Bioventures, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it.
F2: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Bioventures, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P.
F3: Devon Park Associates, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it.
F4: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Associates, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2017 Filed Jan 6, 2017 22:03 UTC | ROCKET PHARMACEUTICALS, INC. ITEK · Entity 5627 | OtherCommon Stock | 9,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001008 · doc1.xml · nonDerivative · entry 2 DEVON PARK BIOVENTURES LP · CIK 0001356034 · 10% owner Devon Park Associates, L.P. · CIK 0001610919 · 10% owner Devon Park Associates, LLC · CIK 0001610920 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · kind: Devon Park Associates, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it. F4 · ownership.nature: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Associates, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:03 UTC | ROCKET PHARMACEUTICALS, INC. ITEK · Entity 5627 | OtherCommon Stock | 3,243,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001008 · doc1.xml · nonDerivative · entry 1 DEVON PARK BIOVENTURES LP · CIK 0001356034 · 10% owner Devon Park Associates, L.P. · CIK 0001610919 · 10% owner Devon Park Associates, LLC · CIK 0001610920 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,857 F1 · kind: Devon Park Bioventures, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it. F2 · ownership.nature: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Bioventures, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.